Cargando…

An Automated Organoid Platform with Inter-organoid Homogeneity and Inter-patient Heterogeneity

Current organoid technologies require intensive manual manipulation and lack uniformity in organoid size and cell composition. We present here an automated organoid platform that generates uniform organoid precursors in high-throughput. This is achieved by templating from monodisperse Matrigel dropl...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Shengwei, Zhao, Haoran, Zhang, Weijie, Wang, Jiaqi, Liu, Yuhong, Cao, Yuanxiong, Zheng, Honghui, Hu, Zhiwei, Wang, Shubin, Zhu, Yu, Wang, Wei, Cui, Shuzhong, Lobie, Peter E., Huang, Laiqiang, Ma, Shaohua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7762778/
https://www.ncbi.nlm.nih.gov/pubmed/33377132
http://dx.doi.org/10.1016/j.xcrm.2020.100161
Descripción
Sumario:Current organoid technologies require intensive manual manipulation and lack uniformity in organoid size and cell composition. We present here an automated organoid platform that generates uniform organoid precursors in high-throughput. This is achieved by templating from monodisperse Matrigel droplets and sequentially delivering them into wells using a synchronized microfluidic droplet printer. Each droplet encapsulates a certain number of cells (e.g., 1,500 cells), which statistically represent the heterogeneous cell population in a tumor section. The system produces >400-μm organoids within 1 week with both inter-organoid homogeneity and inter-patient heterogeneity. This enables automated organoid printing to obtain one organoid per well. The organoids recapitulate 97% gene mutations in the parental tumor and reflect the patient-to-patient variation in drug response and sensitivity, from which we obtained more than 80% accuracy among the 21 patients investigated. This organoid platform is anticipated to fulfill the personalized medicine goal of 1-week high-throughput screening for cancer patients.